SynthesisInternational journal of cardiology2021
From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19.
Synthesis in International journal of cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Effect of COVID-19 on Retinal and Choroidal Microvasculature in the Pediatric Population: A Literature Review.Medicina (Kaunas, Lithuania) · 2026Review
- Infectious diseases, cardio-cerebrovascular health and vaccines: pathways to prevention.Aging clinical and experimental research · 2025Review
- Choroidal vascularity ındex findings ın patients recovered from mild course COVID-19 pneumonia.International ophthalmology · 2025Article
- Long-term effect of SARS-CoV-2 infection on cardiovascular outcomes and all-cause mortality.Life sciences · 2022Review
- Retinal microvascular morphology versus COVID-19: What to anticipate?Photodiagnosis and photodynamic therapy · 2022Article
- [Myositis as a post-acute sequela of COVID-19 disease? : Even in times of the pandemic, muscle biopsies can only be assessed in the context of accurate clinical information].Pathologie (Heidelberg, Germany) · 2022Article
- SARS-CoV-2 infection markedly increases long-term cardiovascular risk.European heart journal · 2022Article
- Immunopathological changes, complications, sequelae and immunological memory in COVID-19 patients.Heliyon · 2022Review
- Therapeutic-dose heparin should integrate the standard of care of moderately ill patients with COVID-19 admitted to hospital.European heart journal · 2022Article
- The state of complement in COVID-19.Nature reviews. Immunology · 2022Review
- Neurological update: COVID-19.Journal of neurology · 2021Review
- The role of antirheumatics in patients with COVID-19.The Lancet. Rheumatology · 2021Review
- COVID 19: in the eye of the cytokine storm.European heart journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We concisely review clinical, autopsy, experimental and molecular data of 2019 coronavirus disease (COVID-19). Angiotensin-converting enzyme 2 disruption and thromboinflammatory microangiopathy emerge as distinctive features. Briefly, entry of the virus into microvessels can profoundly disrupt the local renin-angiotensin system, cause endothelial injury, activate the complement cascade and induce powerful thromboinflammatory reactions, involving, in particular, von Willebrand factor, that, if widespread, may lead to microvascular plugging, ischemia and, ultimately, organ failure. We believe the current COVID-19 data consolidate a widely unrecognised paradigm of potentially fatal thromboinflammatory microvascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.